[1]余利军,施星臣,李晓强,等.复方骨质增生缓释片含量测定和体外释放度研究[J].西部中医药,2020,33(03):45-48.[doi:10.12174/j.issn.1004-6852.2020.03.12]
 YU Lijun,SHI Xingchen,LI Xiaoqiang,et al.Study on Content Determination of Compound Anti-hyperosteogeny Sustained - release Tablets and In - vitro Release Degree[J].Western Journal of Traditional Chinese Medicine,2020,33(03):45-48.[doi:10.12174/j.issn.1004-6852.2020.03.12]
点击复制

复方骨质增生缓释片含量测定和体外释放度研究
分享到:

《西部中医药》[ISSN:2096-9600/CN:62-1204/R]

卷:
33
期数:
2020年03期
页码:
45-48
栏目:
方药·质量分析
出版日期:
2020-03-15

文章信息/Info

Title:
Study on Content Determination of Compound Anti-hyperosteogeny Sustained - release Tablets and In - vitro Release Degree
文章编号:
1004-6852(2020)03-0045-04
作者:
余利军施星臣李晓强张伟
1 甘肃省人民医院,甘肃 兰州 730000; 2 兰州市第二人民医院;3 兰州大学第二医院; 4 甘肃省康复中心医院
Author(s):
YU Lijun1 SHI Xingchen2△ LI Xiaoqiang3 ZHANG Wei4
1 Gansu Provincial Hospital, Lanzhou 730000, China; 2 The Second People′s Hospital of Lanzhou City;3 Lanzhou University Second Hospital; 4 Gansu Provincial Rehabilitation Central Hospital
关键词:
复方骨质增生缓释片含量测定体外释药
Keywords:
compound anti-hyperosteogeny sustained-release tablets content determination in-vitro release
分类号:
R921
DOI:
10.12174/j.issn.1004-6852.2020.03.12
摘要:
目的:制定复方骨质增生缓释片的含量测定方法并考察其体外释放度。方法:采用高效液相色谱法(high performance liquid chromatography,HPLC)对复方骨质增生缓释片中金丝桃苷和槲皮素进行含量测定方法学研究;采用正交实验,以金丝桃苷和槲皮素的释放为指标,优选制备工艺,并进行体外累积释放度测定。结果:色谱柱为Agilent Eclipse XDB-C18(250 mm×4.6 mm,5 μm);流动相:乙腈(A)-0.1%磷酸水溶液(B),梯度洗脱条件:0~18 min,14.5%A;18~60 min,14.5%~25.0%A。检测波长:360 nm;柱温:30℃;流速:1.0 mL/min;该测定条件下金丝桃苷和槲皮素浓度分别在3.44~50.04 μg/mL和3.74~59.90 μg/mL,线性范围内呈良好线性关系。方法学稳定。复方骨质增生缓释片中每片含金丝桃苷(8.62±0.43)μg,槲皮素(10.38±0.58)μg。优化的复方骨质增生缓释片处方为羟丙基甲基纤维素36 g,乳糖24 g,微晶纤维素 20 g,所得缓释片体外释药曲线符合缓释制剂的要求。结论:复方骨质增生缓释片含量测定方法快捷简便、稳定、可靠,处方工艺简单可行,缓释效果明显。
Abstract:
Objective: To establish the method of detecting the contents of compound anti-hyperosteogeny sustained - release tablets and investigate its in - vitro release degree. Methods: HPLC method was used to perform content methodology research for hyperin and quercetin in compound anti-hyperosteogeny sustained-release tablets;orthogonal experiment was adopted to optimize the preparation technology amd detect in -vitro cumulative release degree by taking the release of hyperin and quercetin as the indexes. Results: Agilent Eclipse XDB-C18(250 mm×4.6 mm, 5 μm); mobile phase: acetonitrile (A)- 0.1% phosphoric acid aqueous solution (B), the conditions for gradient elution were: 0~18 min, 14.5%A: 18~60 min, 14.5%~25.0%A. Detection wavelengthen: 360 nm; column temperature:30℃; flow rate: 1.0 mL/min; hyperin and quercetin presented good linear relationship in the range from 3.44 to 50.04 μg/mL and from 3.74 to 59.90 μg/mL under the detection conditions. The methodology was stable. Each of compound anti-hyperosteogeny sustained - release tablets contained hyperin (8.62±0.43)μg and quercetin (10.38±0.58)μg. The optimized prescription of compound anti-hyperosteogeny sustained-release tablet was HPMC 36 g, lactin 24 g and MCC 20 g. In-vitro release curve of the tablets met the requirements of the preparations. Conclusion: The method for content determination of compound anti-hyperosteogeny sustained-release tablets is rapid, convenient, stable and reliable, the formulation process is simple and feasible and it shows notable delayed -release effects.

相似文献/References:

[1]谷陟欣,辛秀,刘淑妦,等.改进硫酸-苯酚法测定阿胶口服液中粗多糖含量[J].西部中医药,2011,24(11):13.
[2]吴忠民,贾 忠△,李喜香,等.黄芪党参颗粒中黄芪甲苷含量的HPLC测定方法[J].西部中医药,2012,25(10):23.
 WU Zhong-min,JIA Zhong,LI Xi-xiang,et al.HPLC Determination of Astragaloside Ⅳ in HuangQi DangShen Granule[J].Western Journal of Traditional Chinese Medicine,2012,25(03):23.
[3]周修森,方永凯.HPLC法测定柴丹疏利胶囊中丹参素的含量[J].西部中医药,2012,25(10):25.
 ZHOU Xiu-sen,FANG Yong-kai.Content Determination of DanShenSu in ChaiDan ShuLi Capsule with HPLC[J].Western Journal of Traditional Chinese Medicine,2012,25(03):25.
[4]宋薇,石晓峰△.HPLC 法测定复方红景天口含片中二苯乙烯苷的含量*[J].西部中医药,2012,25(11):31.
 SONG Wei,SHI Xiao-feng.Content Determination of Stilbene Glycoside in Compound Herba Rhodiolae Buccal Tablets with HPLC[J].Western Journal of Traditional Chinese Medicine,2012,25(03):31.
[5]黄文华,宋艳刚,谭隋子,等.穿心莲片中重金属及有害元素的测定*[J].西部中医药,2013,26(05):18.
 HUANG Wenhua,SONG Yangang,TAN Suizi,et al.Determination of Heavy metal and Harmful Elements in ChuanXinLian Tablets[J].Western Journal of Traditional Chinese Medicine,2013,26(03):18.
[6]梁云,李彩东△,张伟,等.不同产地珠子草药材中有效成分咖啡酸含量的测定*[J].西部中医药,2013,26(05):22.
 LIANG Yun,LI Caidong,ZHANG Wei,et al.Determination of Caffeic Acid in ZhuZiCao from Different Producing Areas[J].Western Journal of Traditional Chinese Medicine,2013,26(03):22.
[7]郭钰龙,王谨慧,靳子明,等.RP-HPLC法测定展筋酊中大黄素、大黄酚的含量*[J].西部中医药,2013,26(05):24.
 GUO Yulong,WANG Jinhui,JIN Ziming,et al.Content Determination of Emodin and Chrysophanol in ZhanJing Tincture by RP-HPLC[J].Western Journal of Traditional Chinese Medicine,2013,26(03):24.
[8]李樱,李亚芳,程合丽.海龙蛤蚧口服液中淫羊藿苷的含量测定[J].西部中医药,2013,26(08):22.
 LI Ying,LI Yafang,CHENG Heli.Content Determination of Icariin in HaiLong Gejie Oral Liquid[J].Western Journal of Traditional Chinese Medicine,2013,26(03):22.
[9]毕建云,顾正位,靳光乾,等.黄连汤制炉甘石的鉴别及氧化锌含量测定*[J].西部中医药,2013,26(09):29.
 BI Jianyun,GU Zhengwei,JIN Guanqian,et al.Content Determination of Zinc Oxide and Identification of Processed Calamine by HuangLianTang[J].Western Journal of Traditional Chinese Medicine,2013,26(03):29.
[10]李彩东,王信,张伟.参芪心舒胶囊中黄芪甲苷、芍药苷和丹参酮ⅡA含量的测定*[J].西部中医药,2013,26(10):17.
 LI Caidong,WANG Xin,ZHANG Wei.Assaying of Astragaloside Ⅳ, Peoniflorin and TanshinoneⅡA in ShenQi XinShu Capsule[J].Western Journal of Traditional Chinese Medicine,2013,26(03):17.

备注/Memo

备注/Memo:
收稿日期:2019-01-30*基金项目:甘肃省青年科技基金(1506RJYA315)。作者简介:余利军(1968—),女,副主任药师。研究方向:医院药物制剂和肠内肠外营养。△通讯作者:施星臣(1980—),男,副主任医师。研究方向:骨关节疾病的诊治。
更新日期/Last Update: 2020-03-15